Life
Eli Lilly Acquires Kelonia Therapeutics for $3.25 Billion After Challenging Journey
The acquisition of Kelonia Therapeutics by Eli Lilly for $3.25 billion marks a significant turn for the struggling biotech firm, which faced numerous challenges.
Editorial Staff
1 min read
Updated 4 days ago
Summary
Eli Lilly has announced its acquisition of Kelonia Therapeutics for $3.25 billion, a move that highlights the biotech company's tumultuous history.
Kelonia Therapeutics, a small player in the biotech sector, has faced significant hurdles in its quest for stability and growth.
This acquisition could signal a new chapter for Kelonia, as it transitions under the umbrella of a larger, more established pharmaceutical entity.
Key Facts
| Fact | Value |
|---|---|
| Acquisition Amount | $3.25 billion |
| Acquirer | Eli Lilly |
| Target Company | Kelonia Therapeutics |
Updates
- No subsequent updates recorded.